$InflaRx(IFRX)$

InflaRx Reports Full Year 2021 Financial and Operating Results

•Company received corrected FDA advice letter for Phase III trial with vilobelimab in hidradenitis suppurativa

•Positive Phase IIa data reported with vilobelimab in pyoderma gangrenosum; data being presented as late-breaker oral presentation at AAD Annual Meeting

•Topline data in vilobelimab Phase III trial in severe COVID-19 expected by end of March

•Both US and EU Phase II trials with vilobelimab in AAV met their objectives

•Phase II trial with vilobelimab in cSCC enrolling with first efficacy data expected later this year

•New program, INF904 oral small molecule inhibitor of C5aR, recently introduced

•Year-end cash and cash equivalents of approximately €26.2 million and financial assets of approximately €84.4 million